Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes
The pleiotropic effects of SGLT2 inhibition leading to the reduction in hospitalization and improvement of quality of life in heart failure (HF) patients. SGLT2 inhibitors act through antioxidant (yellow), anti-inflammatory (orange), and anti-fibrotic (purple) pathways, while also promoting autophag...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Theofilis, Panagiotis [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2022transfer abstract |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Rewritable superhemophobic and superhemophilic wettability pattern based on titanium dioxide with Ag loading - Tran, Minh Quang ELSEVIER, 2018, the official journal of the International Diabetes Federation, West Pacific Region, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:188 ; year:2022 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.diabres.2022.109927 |
|---|
| Katalog-ID: |
ELV058090037 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV058090037 | ||
| 003 | DE-627 | ||
| 005 | 20230626050308.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220808s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.diabres.2022.109927 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001804.pica |
| 035 | |a (DE-627)ELV058090037 | ||
| 035 | |a (ELSEVIER)S0168-8227(22)00741-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 540 |q VZ |
| 084 | |a 35.40 |2 bkl | ||
| 100 | 1 | |a Theofilis, Panagiotis |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes |
| 264 | 1 | |c 2022transfer abstract | |
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a The pleiotropic effects of SGLT2 inhibition leading to the reduction in hospitalization and improvement of quality of life in heart failure (HF) patients. SGLT2 inhibitors act through antioxidant (yellow), anti-inflammatory (orange), and anti-fibrotic (purple) pathways, while also promoting autophagy (blue) in cardiomyocytes. Moreover, they ameliorate endothelial function of cardiac microvascular endothelial cells (CMEC) by improving nitric oxide (NO) bioavailability. Additionally, they aid epicardial adipose tissue (EAT, red) shrinking by downregulating leptin. Ultimately, reversal of adverse cardiac remodeling is being observed, leading to a reduction in HF hospitalizations and improvement of quality of life. eNOS: endothelial NO synthase, PKG: protein kinase G, NOX: NADPH oxidase, THB: tetrahydrobiopterin, ROS: reactive oxygen species, NLRP3-I: NLRP3 inflammasome, NF-κB: nuclear factor kappaB, TGF: transforming growth factor, AMPK: AMP-activated protein kinase, ER: endoplasmic reticulum, | ||
| 520 | |a The pleiotropic effects of SGLT2 inhibition leading to the reduction in hospitalization and improvement of quality of life in heart failure (HF) patients. SGLT2 inhibitors act through antioxidant (yellow), anti-inflammatory (orange), and anti-fibrotic (purple) pathways, while also promoting autophagy (blue) in cardiomyocytes. Moreover, they ameliorate endothelial function of cardiac microvascular endothelial cells (CMEC) by improving nitric oxide (NO) bioavailability. Additionally, they aid epicardial adipose tissue (EAT, red) shrinking by downregulating leptin. Ultimately, reversal of adverse cardiac remodeling is being observed, leading to a reduction in HF hospitalizations and improvement of quality of life. eNOS: endothelial NO synthase, PKG: protein kinase G, NOX: NADPH oxidase, THB: tetrahydrobiopterin, ROS: reactive oxygen species, NLRP3-I: NLRP3 inflammasome, NF-κB: nuclear factor kappaB, TGF: transforming growth factor, AMPK: AMP-activated protein kinase, ER: endoplasmic reticulum, | ||
| 650 | 7 | |a Heart failure |2 Elsevier | |
| 650 | 7 | |a Oxidative stress |2 Elsevier | |
| 650 | 7 | |a Fibrosis |2 Elsevier | |
| 650 | 7 | |a Endothelial dysfunction |2 Elsevier | |
| 650 | 7 | |a Inflammation |2 Elsevier | |
| 650 | 7 | |a Autophagy |2 Elsevier | |
| 650 | 7 | |a SGLT2 inhibitors |2 Elsevier | |
| 700 | 1 | |a Sagris, Marios |4 oth | |
| 700 | 1 | |a Oikonomou, Evangelos |4 oth | |
| 700 | 1 | |a Antonopoulos, Alexios S. |4 oth | |
| 700 | 1 | |a Siasos, Gerasimos |4 oth | |
| 700 | 1 | |a Tsioufis, Kostas |4 oth | |
| 700 | 1 | |a Tousoulis, Dimitris |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Tran, Minh Quang ELSEVIER |t Rewritable superhemophobic and superhemophilic wettability pattern based on titanium dioxide with Ag loading |d 2018 |d the official journal of the International Diabetes Federation, West Pacific Region |g Amsterdam [u.a.] |w (DE-627)ELV000433934 |
| 773 | 1 | 8 | |g volume:188 |g year:2022 |g pages:0 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.diabres.2022.109927 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 936 | b | k | |a 35.40 |j Anorganische Chemie: Allgemeines |q VZ |
| 951 | |a AR | ||
| 952 | |d 188 |j 2022 |h 0 | ||
| author_variant |
p t pt |
|---|---|
| matchkey_str |
theofilispanagiotissagrismariosoikonomou:2022----:litoiefcsfgtihbtrader |
| hierarchy_sort_str |
2022transfer abstract |
| bklnumber |
35.40 |
| publishDate |
2022 |
| allfields |
10.1016/j.diabres.2022.109927 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001804.pica (DE-627)ELV058090037 (ELSEVIER)S0168-8227(22)00741-0 DE-627 ger DE-627 rakwb eng 540 VZ 35.40 bkl Theofilis, Panagiotis verfasserin aut Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes 2022transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The pleiotropic effects of SGLT2 inhibition leading to the reduction in hospitalization and improvement of quality of life in heart failure (HF) patients. SGLT2 inhibitors act through antioxidant (yellow), anti-inflammatory (orange), and anti-fibrotic (purple) pathways, while also promoting autophagy (blue) in cardiomyocytes. Moreover, they ameliorate endothelial function of cardiac microvascular endothelial cells (CMEC) by improving nitric oxide (NO) bioavailability. Additionally, they aid epicardial adipose tissue (EAT, red) shrinking by downregulating leptin. Ultimately, reversal of adverse cardiac remodeling is being observed, leading to a reduction in HF hospitalizations and improvement of quality of life. eNOS: endothelial NO synthase, PKG: protein kinase G, NOX: NADPH oxidase, THB: tetrahydrobiopterin, ROS: reactive oxygen species, NLRP3-I: NLRP3 inflammasome, NF-κB: nuclear factor kappaB, TGF: transforming growth factor, AMPK: AMP-activated protein kinase, ER: endoplasmic reticulum, The pleiotropic effects of SGLT2 inhibition leading to the reduction in hospitalization and improvement of quality of life in heart failure (HF) patients. SGLT2 inhibitors act through antioxidant (yellow), anti-inflammatory (orange), and anti-fibrotic (purple) pathways, while also promoting autophagy (blue) in cardiomyocytes. Moreover, they ameliorate endothelial function of cardiac microvascular endothelial cells (CMEC) by improving nitric oxide (NO) bioavailability. Additionally, they aid epicardial adipose tissue (EAT, red) shrinking by downregulating leptin. Ultimately, reversal of adverse cardiac remodeling is being observed, leading to a reduction in HF hospitalizations and improvement of quality of life. eNOS: endothelial NO synthase, PKG: protein kinase G, NOX: NADPH oxidase, THB: tetrahydrobiopterin, ROS: reactive oxygen species, NLRP3-I: NLRP3 inflammasome, NF-κB: nuclear factor kappaB, TGF: transforming growth factor, AMPK: AMP-activated protein kinase, ER: endoplasmic reticulum, Heart failure Elsevier Oxidative stress Elsevier Fibrosis Elsevier Endothelial dysfunction Elsevier Inflammation Elsevier Autophagy Elsevier SGLT2 inhibitors Elsevier Sagris, Marios oth Oikonomou, Evangelos oth Antonopoulos, Alexios S. oth Siasos, Gerasimos oth Tsioufis, Kostas oth Tousoulis, Dimitris oth Enthalten in Elsevier Science Tran, Minh Quang ELSEVIER Rewritable superhemophobic and superhemophilic wettability pattern based on titanium dioxide with Ag loading 2018 the official journal of the International Diabetes Federation, West Pacific Region Amsterdam [u.a.] (DE-627)ELV000433934 volume:188 year:2022 pages:0 https://doi.org/10.1016/j.diabres.2022.109927 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 35.40 Anorganische Chemie: Allgemeines VZ AR 188 2022 0 |
| spelling |
10.1016/j.diabres.2022.109927 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001804.pica (DE-627)ELV058090037 (ELSEVIER)S0168-8227(22)00741-0 DE-627 ger DE-627 rakwb eng 540 VZ 35.40 bkl Theofilis, Panagiotis verfasserin aut Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes 2022transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The pleiotropic effects of SGLT2 inhibition leading to the reduction in hospitalization and improvement of quality of life in heart failure (HF) patients. SGLT2 inhibitors act through antioxidant (yellow), anti-inflammatory (orange), and anti-fibrotic (purple) pathways, while also promoting autophagy (blue) in cardiomyocytes. Moreover, they ameliorate endothelial function of cardiac microvascular endothelial cells (CMEC) by improving nitric oxide (NO) bioavailability. Additionally, they aid epicardial adipose tissue (EAT, red) shrinking by downregulating leptin. Ultimately, reversal of adverse cardiac remodeling is being observed, leading to a reduction in HF hospitalizations and improvement of quality of life. eNOS: endothelial NO synthase, PKG: protein kinase G, NOX: NADPH oxidase, THB: tetrahydrobiopterin, ROS: reactive oxygen species, NLRP3-I: NLRP3 inflammasome, NF-κB: nuclear factor kappaB, TGF: transforming growth factor, AMPK: AMP-activated protein kinase, ER: endoplasmic reticulum, The pleiotropic effects of SGLT2 inhibition leading to the reduction in hospitalization and improvement of quality of life in heart failure (HF) patients. SGLT2 inhibitors act through antioxidant (yellow), anti-inflammatory (orange), and anti-fibrotic (purple) pathways, while also promoting autophagy (blue) in cardiomyocytes. Moreover, they ameliorate endothelial function of cardiac microvascular endothelial cells (CMEC) by improving nitric oxide (NO) bioavailability. Additionally, they aid epicardial adipose tissue (EAT, red) shrinking by downregulating leptin. Ultimately, reversal of adverse cardiac remodeling is being observed, leading to a reduction in HF hospitalizations and improvement of quality of life. eNOS: endothelial NO synthase, PKG: protein kinase G, NOX: NADPH oxidase, THB: tetrahydrobiopterin, ROS: reactive oxygen species, NLRP3-I: NLRP3 inflammasome, NF-κB: nuclear factor kappaB, TGF: transforming growth factor, AMPK: AMP-activated protein kinase, ER: endoplasmic reticulum, Heart failure Elsevier Oxidative stress Elsevier Fibrosis Elsevier Endothelial dysfunction Elsevier Inflammation Elsevier Autophagy Elsevier SGLT2 inhibitors Elsevier Sagris, Marios oth Oikonomou, Evangelos oth Antonopoulos, Alexios S. oth Siasos, Gerasimos oth Tsioufis, Kostas oth Tousoulis, Dimitris oth Enthalten in Elsevier Science Tran, Minh Quang ELSEVIER Rewritable superhemophobic and superhemophilic wettability pattern based on titanium dioxide with Ag loading 2018 the official journal of the International Diabetes Federation, West Pacific Region Amsterdam [u.a.] (DE-627)ELV000433934 volume:188 year:2022 pages:0 https://doi.org/10.1016/j.diabres.2022.109927 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 35.40 Anorganische Chemie: Allgemeines VZ AR 188 2022 0 |
| allfields_unstemmed |
10.1016/j.diabres.2022.109927 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001804.pica (DE-627)ELV058090037 (ELSEVIER)S0168-8227(22)00741-0 DE-627 ger DE-627 rakwb eng 540 VZ 35.40 bkl Theofilis, Panagiotis verfasserin aut Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes 2022transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The pleiotropic effects of SGLT2 inhibition leading to the reduction in hospitalization and improvement of quality of life in heart failure (HF) patients. SGLT2 inhibitors act through antioxidant (yellow), anti-inflammatory (orange), and anti-fibrotic (purple) pathways, while also promoting autophagy (blue) in cardiomyocytes. Moreover, they ameliorate endothelial function of cardiac microvascular endothelial cells (CMEC) by improving nitric oxide (NO) bioavailability. Additionally, they aid epicardial adipose tissue (EAT, red) shrinking by downregulating leptin. Ultimately, reversal of adverse cardiac remodeling is being observed, leading to a reduction in HF hospitalizations and improvement of quality of life. eNOS: endothelial NO synthase, PKG: protein kinase G, NOX: NADPH oxidase, THB: tetrahydrobiopterin, ROS: reactive oxygen species, NLRP3-I: NLRP3 inflammasome, NF-κB: nuclear factor kappaB, TGF: transforming growth factor, AMPK: AMP-activated protein kinase, ER: endoplasmic reticulum, The pleiotropic effects of SGLT2 inhibition leading to the reduction in hospitalization and improvement of quality of life in heart failure (HF) patients. SGLT2 inhibitors act through antioxidant (yellow), anti-inflammatory (orange), and anti-fibrotic (purple) pathways, while also promoting autophagy (blue) in cardiomyocytes. Moreover, they ameliorate endothelial function of cardiac microvascular endothelial cells (CMEC) by improving nitric oxide (NO) bioavailability. Additionally, they aid epicardial adipose tissue (EAT, red) shrinking by downregulating leptin. Ultimately, reversal of adverse cardiac remodeling is being observed, leading to a reduction in HF hospitalizations and improvement of quality of life. eNOS: endothelial NO synthase, PKG: protein kinase G, NOX: NADPH oxidase, THB: tetrahydrobiopterin, ROS: reactive oxygen species, NLRP3-I: NLRP3 inflammasome, NF-κB: nuclear factor kappaB, TGF: transforming growth factor, AMPK: AMP-activated protein kinase, ER: endoplasmic reticulum, Heart failure Elsevier Oxidative stress Elsevier Fibrosis Elsevier Endothelial dysfunction Elsevier Inflammation Elsevier Autophagy Elsevier SGLT2 inhibitors Elsevier Sagris, Marios oth Oikonomou, Evangelos oth Antonopoulos, Alexios S. oth Siasos, Gerasimos oth Tsioufis, Kostas oth Tousoulis, Dimitris oth Enthalten in Elsevier Science Tran, Minh Quang ELSEVIER Rewritable superhemophobic and superhemophilic wettability pattern based on titanium dioxide with Ag loading 2018 the official journal of the International Diabetes Federation, West Pacific Region Amsterdam [u.a.] (DE-627)ELV000433934 volume:188 year:2022 pages:0 https://doi.org/10.1016/j.diabres.2022.109927 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 35.40 Anorganische Chemie: Allgemeines VZ AR 188 2022 0 |
| allfieldsGer |
10.1016/j.diabres.2022.109927 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001804.pica (DE-627)ELV058090037 (ELSEVIER)S0168-8227(22)00741-0 DE-627 ger DE-627 rakwb eng 540 VZ 35.40 bkl Theofilis, Panagiotis verfasserin aut Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes 2022transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The pleiotropic effects of SGLT2 inhibition leading to the reduction in hospitalization and improvement of quality of life in heart failure (HF) patients. SGLT2 inhibitors act through antioxidant (yellow), anti-inflammatory (orange), and anti-fibrotic (purple) pathways, while also promoting autophagy (blue) in cardiomyocytes. Moreover, they ameliorate endothelial function of cardiac microvascular endothelial cells (CMEC) by improving nitric oxide (NO) bioavailability. Additionally, they aid epicardial adipose tissue (EAT, red) shrinking by downregulating leptin. Ultimately, reversal of adverse cardiac remodeling is being observed, leading to a reduction in HF hospitalizations and improvement of quality of life. eNOS: endothelial NO synthase, PKG: protein kinase G, NOX: NADPH oxidase, THB: tetrahydrobiopterin, ROS: reactive oxygen species, NLRP3-I: NLRP3 inflammasome, NF-κB: nuclear factor kappaB, TGF: transforming growth factor, AMPK: AMP-activated protein kinase, ER: endoplasmic reticulum, The pleiotropic effects of SGLT2 inhibition leading to the reduction in hospitalization and improvement of quality of life in heart failure (HF) patients. SGLT2 inhibitors act through antioxidant (yellow), anti-inflammatory (orange), and anti-fibrotic (purple) pathways, while also promoting autophagy (blue) in cardiomyocytes. Moreover, they ameliorate endothelial function of cardiac microvascular endothelial cells (CMEC) by improving nitric oxide (NO) bioavailability. Additionally, they aid epicardial adipose tissue (EAT, red) shrinking by downregulating leptin. Ultimately, reversal of adverse cardiac remodeling is being observed, leading to a reduction in HF hospitalizations and improvement of quality of life. eNOS: endothelial NO synthase, PKG: protein kinase G, NOX: NADPH oxidase, THB: tetrahydrobiopterin, ROS: reactive oxygen species, NLRP3-I: NLRP3 inflammasome, NF-κB: nuclear factor kappaB, TGF: transforming growth factor, AMPK: AMP-activated protein kinase, ER: endoplasmic reticulum, Heart failure Elsevier Oxidative stress Elsevier Fibrosis Elsevier Endothelial dysfunction Elsevier Inflammation Elsevier Autophagy Elsevier SGLT2 inhibitors Elsevier Sagris, Marios oth Oikonomou, Evangelos oth Antonopoulos, Alexios S. oth Siasos, Gerasimos oth Tsioufis, Kostas oth Tousoulis, Dimitris oth Enthalten in Elsevier Science Tran, Minh Quang ELSEVIER Rewritable superhemophobic and superhemophilic wettability pattern based on titanium dioxide with Ag loading 2018 the official journal of the International Diabetes Federation, West Pacific Region Amsterdam [u.a.] (DE-627)ELV000433934 volume:188 year:2022 pages:0 https://doi.org/10.1016/j.diabres.2022.109927 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 35.40 Anorganische Chemie: Allgemeines VZ AR 188 2022 0 |
| allfieldsSound |
10.1016/j.diabres.2022.109927 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001804.pica (DE-627)ELV058090037 (ELSEVIER)S0168-8227(22)00741-0 DE-627 ger DE-627 rakwb eng 540 VZ 35.40 bkl Theofilis, Panagiotis verfasserin aut Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes 2022transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The pleiotropic effects of SGLT2 inhibition leading to the reduction in hospitalization and improvement of quality of life in heart failure (HF) patients. SGLT2 inhibitors act through antioxidant (yellow), anti-inflammatory (orange), and anti-fibrotic (purple) pathways, while also promoting autophagy (blue) in cardiomyocytes. Moreover, they ameliorate endothelial function of cardiac microvascular endothelial cells (CMEC) by improving nitric oxide (NO) bioavailability. Additionally, they aid epicardial adipose tissue (EAT, red) shrinking by downregulating leptin. Ultimately, reversal of adverse cardiac remodeling is being observed, leading to a reduction in HF hospitalizations and improvement of quality of life. eNOS: endothelial NO synthase, PKG: protein kinase G, NOX: NADPH oxidase, THB: tetrahydrobiopterin, ROS: reactive oxygen species, NLRP3-I: NLRP3 inflammasome, NF-κB: nuclear factor kappaB, TGF: transforming growth factor, AMPK: AMP-activated protein kinase, ER: endoplasmic reticulum, The pleiotropic effects of SGLT2 inhibition leading to the reduction in hospitalization and improvement of quality of life in heart failure (HF) patients. SGLT2 inhibitors act through antioxidant (yellow), anti-inflammatory (orange), and anti-fibrotic (purple) pathways, while also promoting autophagy (blue) in cardiomyocytes. Moreover, they ameliorate endothelial function of cardiac microvascular endothelial cells (CMEC) by improving nitric oxide (NO) bioavailability. Additionally, they aid epicardial adipose tissue (EAT, red) shrinking by downregulating leptin. Ultimately, reversal of adverse cardiac remodeling is being observed, leading to a reduction in HF hospitalizations and improvement of quality of life. eNOS: endothelial NO synthase, PKG: protein kinase G, NOX: NADPH oxidase, THB: tetrahydrobiopterin, ROS: reactive oxygen species, NLRP3-I: NLRP3 inflammasome, NF-κB: nuclear factor kappaB, TGF: transforming growth factor, AMPK: AMP-activated protein kinase, ER: endoplasmic reticulum, Heart failure Elsevier Oxidative stress Elsevier Fibrosis Elsevier Endothelial dysfunction Elsevier Inflammation Elsevier Autophagy Elsevier SGLT2 inhibitors Elsevier Sagris, Marios oth Oikonomou, Evangelos oth Antonopoulos, Alexios S. oth Siasos, Gerasimos oth Tsioufis, Kostas oth Tousoulis, Dimitris oth Enthalten in Elsevier Science Tran, Minh Quang ELSEVIER Rewritable superhemophobic and superhemophilic wettability pattern based on titanium dioxide with Ag loading 2018 the official journal of the International Diabetes Federation, West Pacific Region Amsterdam [u.a.] (DE-627)ELV000433934 volume:188 year:2022 pages:0 https://doi.org/10.1016/j.diabres.2022.109927 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 35.40 Anorganische Chemie: Allgemeines VZ AR 188 2022 0 |
| language |
English |
| source |
Enthalten in Rewritable superhemophobic and superhemophilic wettability pattern based on titanium dioxide with Ag loading Amsterdam [u.a.] volume:188 year:2022 pages:0 |
| sourceStr |
Enthalten in Rewritable superhemophobic and superhemophilic wettability pattern based on titanium dioxide with Ag loading Amsterdam [u.a.] volume:188 year:2022 pages:0 |
| format_phy_str_mv |
Article |
| bklname |
Anorganische Chemie: Allgemeines |
| institution |
findex.gbv.de |
| topic_facet |
Heart failure Oxidative stress Fibrosis Endothelial dysfunction Inflammation Autophagy SGLT2 inhibitors |
| dewey-raw |
540 |
| isfreeaccess_bool |
false |
| container_title |
Rewritable superhemophobic and superhemophilic wettability pattern based on titanium dioxide with Ag loading |
| authorswithroles_txt_mv |
Theofilis, Panagiotis @@aut@@ Sagris, Marios @@oth@@ Oikonomou, Evangelos @@oth@@ Antonopoulos, Alexios S. @@oth@@ Siasos, Gerasimos @@oth@@ Tsioufis, Kostas @@oth@@ Tousoulis, Dimitris @@oth@@ |
| publishDateDaySort_date |
2022-01-01T00:00:00Z |
| hierarchy_top_id |
ELV000433934 |
| dewey-sort |
3540 |
| id |
ELV058090037 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV058090037</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626050308.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220808s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.diabres.2022.109927</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001804.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV058090037</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0168-8227(22)00741-0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.40</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Theofilis, Panagiotis</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022transfer abstract</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The pleiotropic effects of SGLT2 inhibition leading to the reduction in hospitalization and improvement of quality of life in heart failure (HF) patients. SGLT2 inhibitors act through antioxidant (yellow), anti-inflammatory (orange), and anti-fibrotic (purple) pathways, while also promoting autophagy (blue) in cardiomyocytes. Moreover, they ameliorate endothelial function of cardiac microvascular endothelial cells (CMEC) by improving nitric oxide (NO) bioavailability. Additionally, they aid epicardial adipose tissue (EAT, red) shrinking by downregulating leptin. Ultimately, reversal of adverse cardiac remodeling is being observed, leading to a reduction in HF hospitalizations and improvement of quality of life. eNOS: endothelial NO synthase, PKG: protein kinase G, NOX: NADPH oxidase, THB: tetrahydrobiopterin, ROS: reactive oxygen species, NLRP3-I: NLRP3 inflammasome, NF-κB: nuclear factor kappaB, TGF: transforming growth factor, AMPK: AMP-activated protein kinase, ER: endoplasmic reticulum,</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The pleiotropic effects of SGLT2 inhibition leading to the reduction in hospitalization and improvement of quality of life in heart failure (HF) patients. SGLT2 inhibitors act through antioxidant (yellow), anti-inflammatory (orange), and anti-fibrotic (purple) pathways, while also promoting autophagy (blue) in cardiomyocytes. Moreover, they ameliorate endothelial function of cardiac microvascular endothelial cells (CMEC) by improving nitric oxide (NO) bioavailability. Additionally, they aid epicardial adipose tissue (EAT, red) shrinking by downregulating leptin. Ultimately, reversal of adverse cardiac remodeling is being observed, leading to a reduction in HF hospitalizations and improvement of quality of life. eNOS: endothelial NO synthase, PKG: protein kinase G, NOX: NADPH oxidase, THB: tetrahydrobiopterin, ROS: reactive oxygen species, NLRP3-I: NLRP3 inflammasome, NF-κB: nuclear factor kappaB, TGF: transforming growth factor, AMPK: AMP-activated protein kinase, ER: endoplasmic reticulum,</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Heart failure</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Oxidative stress</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Fibrosis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Endothelial dysfunction</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Inflammation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Autophagy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SGLT2 inhibitors</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sagris, Marios</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Oikonomou, Evangelos</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Antonopoulos, Alexios S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Siasos, Gerasimos</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tsioufis, Kostas</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tousoulis, Dimitris</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Tran, Minh Quang ELSEVIER</subfield><subfield code="t">Rewritable superhemophobic and superhemophilic wettability pattern based on titanium dioxide with Ag loading</subfield><subfield code="d">2018</subfield><subfield code="d">the official journal of the International Diabetes Federation, West Pacific Region</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000433934</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:188</subfield><subfield code="g">year:2022</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.diabres.2022.109927</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.40</subfield><subfield code="j">Anorganische Chemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">188</subfield><subfield code="j">2022</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| author |
Theofilis, Panagiotis |
| spellingShingle |
Theofilis, Panagiotis ddc 540 bkl 35.40 Elsevier Heart failure Elsevier Oxidative stress Elsevier Fibrosis Elsevier Endothelial dysfunction Elsevier Inflammation Elsevier Autophagy Elsevier SGLT2 inhibitors Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes |
| authorStr |
Theofilis, Panagiotis |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000433934 |
| format |
electronic Article |
| dewey-ones |
540 - Chemistry & allied sciences |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
540 VZ 35.40 bkl Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes Heart failure Elsevier Oxidative stress Elsevier Fibrosis Elsevier Endothelial dysfunction Elsevier Inflammation Elsevier Autophagy Elsevier SGLT2 inhibitors Elsevier |
| topic |
ddc 540 bkl 35.40 Elsevier Heart failure Elsevier Oxidative stress Elsevier Fibrosis Elsevier Endothelial dysfunction Elsevier Inflammation Elsevier Autophagy Elsevier SGLT2 inhibitors |
| topic_unstemmed |
ddc 540 bkl 35.40 Elsevier Heart failure Elsevier Oxidative stress Elsevier Fibrosis Elsevier Endothelial dysfunction Elsevier Inflammation Elsevier Autophagy Elsevier SGLT2 inhibitors |
| topic_browse |
ddc 540 bkl 35.40 Elsevier Heart failure Elsevier Oxidative stress Elsevier Fibrosis Elsevier Endothelial dysfunction Elsevier Inflammation Elsevier Autophagy Elsevier SGLT2 inhibitors |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
m s ms e o eo a s a as asa g s gs k t kt d t dt |
| hierarchy_parent_title |
Rewritable superhemophobic and superhemophilic wettability pattern based on titanium dioxide with Ag loading |
| hierarchy_parent_id |
ELV000433934 |
| dewey-tens |
540 - Chemistry |
| hierarchy_top_title |
Rewritable superhemophobic and superhemophilic wettability pattern based on titanium dioxide with Ag loading |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV000433934 |
| title |
Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes |
| ctrlnum |
(DE-627)ELV058090037 (ELSEVIER)S0168-8227(22)00741-0 |
| title_full |
Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes |
| author_sort |
Theofilis, Panagiotis |
| journal |
Rewritable superhemophobic and superhemophilic wettability pattern based on titanium dioxide with Ag loading |
| journalStr |
Rewritable superhemophobic and superhemophilic wettability pattern based on titanium dioxide with Ag loading |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
500 - Science |
| recordtype |
marc |
| publishDateSort |
2022 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
Theofilis, Panagiotis |
| container_volume |
188 |
| class |
540 VZ 35.40 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Theofilis, Panagiotis |
| doi_str_mv |
10.1016/j.diabres.2022.109927 |
| dewey-full |
540 |
| title_sort |
pleiotropic effects of sglt2 inhibitors and heart failure outcomes |
| title_auth |
Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes |
| abstract |
The pleiotropic effects of SGLT2 inhibition leading to the reduction in hospitalization and improvement of quality of life in heart failure (HF) patients. SGLT2 inhibitors act through antioxidant (yellow), anti-inflammatory (orange), and anti-fibrotic (purple) pathways, while also promoting autophagy (blue) in cardiomyocytes. Moreover, they ameliorate endothelial function of cardiac microvascular endothelial cells (CMEC) by improving nitric oxide (NO) bioavailability. Additionally, they aid epicardial adipose tissue (EAT, red) shrinking by downregulating leptin. Ultimately, reversal of adverse cardiac remodeling is being observed, leading to a reduction in HF hospitalizations and improvement of quality of life. eNOS: endothelial NO synthase, PKG: protein kinase G, NOX: NADPH oxidase, THB: tetrahydrobiopterin, ROS: reactive oxygen species, NLRP3-I: NLRP3 inflammasome, NF-κB: nuclear factor kappaB, TGF: transforming growth factor, AMPK: AMP-activated protein kinase, ER: endoplasmic reticulum, |
| abstractGer |
The pleiotropic effects of SGLT2 inhibition leading to the reduction in hospitalization and improvement of quality of life in heart failure (HF) patients. SGLT2 inhibitors act through antioxidant (yellow), anti-inflammatory (orange), and anti-fibrotic (purple) pathways, while also promoting autophagy (blue) in cardiomyocytes. Moreover, they ameliorate endothelial function of cardiac microvascular endothelial cells (CMEC) by improving nitric oxide (NO) bioavailability. Additionally, they aid epicardial adipose tissue (EAT, red) shrinking by downregulating leptin. Ultimately, reversal of adverse cardiac remodeling is being observed, leading to a reduction in HF hospitalizations and improvement of quality of life. eNOS: endothelial NO synthase, PKG: protein kinase G, NOX: NADPH oxidase, THB: tetrahydrobiopterin, ROS: reactive oxygen species, NLRP3-I: NLRP3 inflammasome, NF-κB: nuclear factor kappaB, TGF: transforming growth factor, AMPK: AMP-activated protein kinase, ER: endoplasmic reticulum, |
| abstract_unstemmed |
The pleiotropic effects of SGLT2 inhibition leading to the reduction in hospitalization and improvement of quality of life in heart failure (HF) patients. SGLT2 inhibitors act through antioxidant (yellow), anti-inflammatory (orange), and anti-fibrotic (purple) pathways, while also promoting autophagy (blue) in cardiomyocytes. Moreover, they ameliorate endothelial function of cardiac microvascular endothelial cells (CMEC) by improving nitric oxide (NO) bioavailability. Additionally, they aid epicardial adipose tissue (EAT, red) shrinking by downregulating leptin. Ultimately, reversal of adverse cardiac remodeling is being observed, leading to a reduction in HF hospitalizations and improvement of quality of life. eNOS: endothelial NO synthase, PKG: protein kinase G, NOX: NADPH oxidase, THB: tetrahydrobiopterin, ROS: reactive oxygen species, NLRP3-I: NLRP3 inflammasome, NF-κB: nuclear factor kappaB, TGF: transforming growth factor, AMPK: AMP-activated protein kinase, ER: endoplasmic reticulum, |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| title_short |
Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes |
| url |
https://doi.org/10.1016/j.diabres.2022.109927 |
| remote_bool |
true |
| author2 |
Sagris, Marios Oikonomou, Evangelos Antonopoulos, Alexios S. Siasos, Gerasimos Tsioufis, Kostas Tousoulis, Dimitris |
| author2Str |
Sagris, Marios Oikonomou, Evangelos Antonopoulos, Alexios S. Siasos, Gerasimos Tsioufis, Kostas Tousoulis, Dimitris |
| ppnlink |
ELV000433934 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth |
| doi_str |
10.1016/j.diabres.2022.109927 |
| up_date |
2024-07-06T18:01:58.906Z |
| _version_ |
1803853673431826432 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV058090037</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626050308.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220808s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.diabres.2022.109927</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001804.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV058090037</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0168-8227(22)00741-0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.40</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Theofilis, Panagiotis</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022transfer abstract</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The pleiotropic effects of SGLT2 inhibition leading to the reduction in hospitalization and improvement of quality of life in heart failure (HF) patients. SGLT2 inhibitors act through antioxidant (yellow), anti-inflammatory (orange), and anti-fibrotic (purple) pathways, while also promoting autophagy (blue) in cardiomyocytes. Moreover, they ameliorate endothelial function of cardiac microvascular endothelial cells (CMEC) by improving nitric oxide (NO) bioavailability. Additionally, they aid epicardial adipose tissue (EAT, red) shrinking by downregulating leptin. Ultimately, reversal of adverse cardiac remodeling is being observed, leading to a reduction in HF hospitalizations and improvement of quality of life. eNOS: endothelial NO synthase, PKG: protein kinase G, NOX: NADPH oxidase, THB: tetrahydrobiopterin, ROS: reactive oxygen species, NLRP3-I: NLRP3 inflammasome, NF-κB: nuclear factor kappaB, TGF: transforming growth factor, AMPK: AMP-activated protein kinase, ER: endoplasmic reticulum,</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The pleiotropic effects of SGLT2 inhibition leading to the reduction in hospitalization and improvement of quality of life in heart failure (HF) patients. SGLT2 inhibitors act through antioxidant (yellow), anti-inflammatory (orange), and anti-fibrotic (purple) pathways, while also promoting autophagy (blue) in cardiomyocytes. Moreover, they ameliorate endothelial function of cardiac microvascular endothelial cells (CMEC) by improving nitric oxide (NO) bioavailability. Additionally, they aid epicardial adipose tissue (EAT, red) shrinking by downregulating leptin. Ultimately, reversal of adverse cardiac remodeling is being observed, leading to a reduction in HF hospitalizations and improvement of quality of life. eNOS: endothelial NO synthase, PKG: protein kinase G, NOX: NADPH oxidase, THB: tetrahydrobiopterin, ROS: reactive oxygen species, NLRP3-I: NLRP3 inflammasome, NF-κB: nuclear factor kappaB, TGF: transforming growth factor, AMPK: AMP-activated protein kinase, ER: endoplasmic reticulum,</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Heart failure</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Oxidative stress</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Fibrosis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Endothelial dysfunction</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Inflammation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Autophagy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SGLT2 inhibitors</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sagris, Marios</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Oikonomou, Evangelos</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Antonopoulos, Alexios S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Siasos, Gerasimos</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tsioufis, Kostas</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tousoulis, Dimitris</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Tran, Minh Quang ELSEVIER</subfield><subfield code="t">Rewritable superhemophobic and superhemophilic wettability pattern based on titanium dioxide with Ag loading</subfield><subfield code="d">2018</subfield><subfield code="d">the official journal of the International Diabetes Federation, West Pacific Region</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000433934</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:188</subfield><subfield code="g">year:2022</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.diabres.2022.109927</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.40</subfield><subfield code="j">Anorganische Chemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">188</subfield><subfield code="j">2022</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.3987713 |